How to cite item

Maximum standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography could replace pathological diagnosis in luminal breast cancer

  
@article{ABS4992,
	author = {Shinya Yamamoto and Shigeru Yamagishi and Toshiro Kohno and Ryosuke Tajiri and Toshikazu Gondo and Yoshimi Fujii and Hiroshi Tsukamoto},
	title = {Maximum standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography could replace pathological diagnosis in luminal breast cancer},
	journal = {Annals of Breast Surgery},
	volume = {3},
	number = {0},
	year = {2019},
	keywords = {},
	abstract = {Background: The maximum standardized uptake value (SUVmax) of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is an essential tool for making a diagnosis and determining treatment response. This study aimed whether the SUVmax of 18F-FDG PET/CT could replace pathological diagnosis in luminal type breast cancer.
Methods: We retrospectively enrolled 85 patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (luminal-type) between August 2013 and January 2018 who underwent 18F-FDG PET/CT scans before surgery and had not received any treatment before surgery at Fujisawa City Hospital. We evaluated the relationship between the SUVmax of 18F-FDG PET/CT and the Ki-67 labeling index (LI) or other clinicopathological features in luminal-type breast cancer; furthermore, we evaluated whether the SUVmax of PET/CT can help determine whether adjuvant chemotherapy is indicated.
Results: The SUVmax differed significantly between the positive and negative groups that showed lymphatic invasion (P=0.018), nuclear grade (P=0.019), and lymph node metastasis (P=0.035). In addition, a significant correlation was observed between the SUVmax and Ki-67 LI (r=0.516, P},
	issn = {2616-2776},	url = {https://abs.amegroups.org/article/view/4992}
}